Tokyo Tape
Sign in
← Carna Biosciences

Annual report

4572.TEDINET S100XSFK
Period2025-01-01 → 2025-12-31
Filed2026-03-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
MetricValuePeriodScopeSource row
Revenue¥579m2025-01-01 → 2025-12-31Cons.Net sales
Revenue¥636m2024-01-01 → 2024-12-31Cons.Net sales
Revenue¥1.6bn2023-01-01 → 2023-12-31vCons.Net sales (5-year summary)
Revenue¥1.4bn2022-01-01 → 2022-12-31vCons.Net sales (5-year summary)
Revenue¥2.0bn2021-01-01 → 2021-12-31dCons.Net sales (5-year summary)
Operating income−¥2.1bn2025-01-01 → 2025-12-31Cons.Operating income
Operating income−¥2.1bn2024-01-01 → 2024-12-31Cons.Operating income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31Cons.Ordinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31Cons.Ordinary income
Ordinary income−¥1.1bn2023-01-01 → 2023-12-31vCons.Ordinary income loss (5-year summary)
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31vCons.Ordinary income loss (5-year summary)
Ordinary income−¥523m2021-01-01 → 2021-12-31dCons.Ordinary income loss (5-year summary)
Profit before tax−¥2.2bn2025-01-01 → 2025-12-31Cons.Income before income taxes
Profit before tax−¥2.2bn2024-01-01 → 2024-12-31Cons.Income before income taxes
Net income (owners)−¥2.2bn2025-01-01 → 2025-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.2bn2023-01-01 → 2023-12-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥534m2021-01-01 → 2021-12-31dCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥2.2bn2025-01-01 → 2025-12-31Cons.Profit loss
Net income−¥2.2bn2024-01-01 → 2024-12-31Cons.Profit loss
Total assets¥1.2bnat 2025-12-31Cons.Assets
Total assets¥2.8bnat 2024-12-31Cons.Assets
Total assets¥4.3bnat 2023-12-31vCons.Total assets (5-year summary)
Total assets¥4.3bnat 2022-12-31vCons.Total assets (5-year summary)
Total assets¥5.4bnat 2021-12-31dCons.Total assets (5-year summary)
Total liabilities¥920mat 2025-12-31Cons.Liabilities
Total liabilities¥297mat 2024-12-31Cons.Liabilities
Net assets / equity¥309mat 2025-12-31Cons.Net assets
Net assets / equity¥2.5bnat 2024-12-31Cons.Net assets
Net assets / equity¥3.9bnat 2023-12-31vCons.Net assets
Net assets / equity¥3.6bnat 2022-12-31vCons.Net assets (5-year summary)
Net assets / equity¥4.3bnat 2021-12-31dCons.Net assets (5-year summary)
Cash and deposits¥517mat 2025-12-31Cons.Cash and deposits
Cash and deposits¥2.1bnat 2024-12-31Cons.Cash and deposits
Cash & equivalents¥517mat 2025-12-31Cons.Cash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31Cons.Cash and cash equivalents
Cash & equivalents¥2.9bnat 2023-12-31vCons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥3.8bnat 2021-12-31dCons.Cash and cash equivalents (5-year summary)
Operating cash flow−¥2.2bn2025-01-01 → 2025-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2024-01-01 → 2024-12-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.7bn2023-01-01 → 2023-12-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥708m2022-01-01 → 2022-12-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.5bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow−¥25m2025-01-01 → 2025-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥13m2024-01-01 → 2024-12-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥11m2023-01-01 → 2023-12-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥126m2022-01-01 → 2022-12-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥42m2021-01-01 → 2021-12-31dCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow¥605m2025-01-01 → 2025-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥567m2024-01-01 → 2024-12-31Cons.Net cash provided by used in financing activities
Financing cash flow¥1.2bn2023-01-01 → 2023-12-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥367m2022-01-01 → 2022-12-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.1bn2021-01-01 → 2021-12-31dCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-113.622025-01-01 → 2025-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-121.642024-01-01 → 2024-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-68.622023-01-01 → 2023-12-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-42.12021-01-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
Net assets per share¥16.16at 2025-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥129.62at 2024-12-31Cons.Net assets per share (5-year summary)
Net assets per share¥226.16at 2023-12-31vCons.Net assets per share (5-year summary)
Net assets per share¥255.04at 2022-12-31vCons.Net assets per share (5-year summary)
Net assets per share¥323.54at 2021-12-31dCons.Net assets per share (5-year summary)
Equity ratio25.1%at 2025-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.3%at 2024-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio89.1%at 2023-12-31vCons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31vCons.Equity to asset ratio (5-year summary)
Equity ratio79.3%at 2021-12-31dCons.Equity to asset ratio (5-year summary)
Employees61at 2025-12-31Cons.Number of employees
Employees63at 2024-12-31Cons.Number of employees
Employees67at 2023-12-31vCons.Number of employees
Employees65at 2022-12-31vCons.Number of employees
Employees64at 2021-12-31dCons.Number of employees
Revenue¥491m2025-01-01 → 2025-12-31StandaloneNet sales
Revenue¥542m2024-01-01 → 2024-12-31StandaloneNet sales
Revenue¥1.5bn2023-01-01 → 2023-12-31vStandaloneNet sales (5-year summary)
Revenue¥1.2bn2022-01-01 → 2022-12-31vStandaloneNet sales (5-year summary)
Revenue¥1.9bn2021-01-01 → 2021-12-31dStandaloneNet sales (5-year summary)
Operating income−¥2.0bn2025-01-01 → 2025-12-31StandaloneOperating income
Operating income−¥2.1bn2024-01-01 → 2024-12-31StandaloneOperating income
Ordinary income−¥2.1bn2025-01-01 → 2025-12-31StandaloneOrdinary income
Ordinary income−¥2.1bn2024-01-01 → 2024-12-31StandaloneOrdinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥1.4bn2022-01-01 → 2022-12-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥549m2021-01-01 → 2021-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥2.1bn2025-01-01 → 2025-12-31StandaloneIncome before income taxes
Profit before tax−¥2.2bn2024-01-01 → 2024-12-31StandaloneIncome before income taxes
Net income−¥2.1bn2025-01-01 → 2025-12-31StandaloneProfit loss
Net income−¥2.2bn2024-01-01 → 2024-12-31StandaloneProfit loss
Net income−¥1.2bn2023-01-01 → 2023-12-31vStandaloneNet income loss (5-year summary)
Net income−¥1.4bn2022-01-01 → 2022-12-31vStandaloneNet income loss (5-year summary)
Net income−¥556m2021-01-01 → 2021-12-31dStandaloneNet income loss (5-year summary)
Total assets¥1.1bnat 2025-12-31StandaloneAssets
Total assets¥2.5bnat 2024-12-31StandaloneAssets
Total assets¥4.1bnat 2023-12-31vStandaloneTotal assets (5-year summary)
Total assets¥4.0bnat 2022-12-31vStandaloneTotal assets (5-year summary)
Total assets¥5.3bnat 2021-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥1.1bnat 2025-12-31StandaloneLiabilities
Total liabilities¥294mat 2024-12-31StandaloneLiabilities
Net assets / equity¥66mat 2025-12-31StandaloneNet assets
Net assets / equity¥2.2bnat 2024-12-31StandaloneNet assets
Net assets / equity¥3.6bnat 2023-12-31vStandaloneNet assets
Net assets / equity¥3.4bnat 2022-12-31vStandaloneNet assets (5-year summary)
Net assets / equity¥4.2bnat 2021-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥413mat 2025-12-31StandaloneCash and deposits
Cash and deposits¥1.8bnat 2024-12-31StandaloneCash and deposits
EPS (basic)¥-112.092025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-121.082024-01-01 → 2024-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-70.532023-01-01 → 2023-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-103.22022-01-01 → 2022-12-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-43.832021-01-01 → 2021-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥3.45at 2025-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥115.11at 2024-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥211.43at 2023-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥240.82at 2022-12-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥314.45at 2021-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio5.8%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.2%at 2024-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio88.7%at 2023-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio84.6%at 2022-12-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio78.9%at 2021-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued19,150,500at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued19,107,500at 2024-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued17,151,900at 2023-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued14,218,300at 2022-12-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued13,313,400at 2021-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees57at 2025-12-31StandaloneNumber of employees
Employees60at 2024-12-31StandaloneNumber of employees
Employees64at 2023-12-31vStandaloneNumber of employees
Employees62at 2022-12-31vStandaloneNumber of employees
Employees61at 2021-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 35
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment assetsat 2025-12-31¥528m
Drug Discovery Businessreportable segmentcapex2025-01-01 → 2025-12-31¥18m
Drug Discovery Businessreportable segmentemployeesat 2025-12-3133 pure
Drug Discovery Businessreportable segmentsegment assetsat 2025-12-31¥313m
Drug Discovery Businessreportable segmentsegment profit2025-01-01 → 2025-12-31−¥2.0bn
Drug Discovery Support Businessreportable segmentcapex2025-01-01 → 2025-12-31¥7m
Drug Discovery Support Businessreportable segmentemployeesat 2025-12-3120 pure
Drug Discovery Support Businessreportable segmentrevenue2025-01-01 → 2025-12-31¥579m
Drug Discovery Support Businessreportable segmentrevenue external2025-01-01 → 2025-12-31¥579m
Drug Discovery Support Businessreportable segmentsegment assetsat 2025-12-31¥388m
Drug Discovery Support Businessreportable segmentsegment profit2025-01-01 → 2025-12-31−¥51m
—segment totalcapex2025-01-01 → 2025-12-31¥25m
—segment totalrevenue2025-01-01 → 2025-12-31¥579m
—segment totalrevenue external2025-01-01 → 2025-12-31¥579m
—segment totalsegment assetsat 2025-12-31¥701m
—segment totalsegment profit2025-01-01 → 2025-12-31−¥2.1bn
Reconciling Itemsreconcilingsegment assetsat 2024-12-31¥1.9bn
Drug Discovery Businessreportable segmentcapex2024-01-01 → 2024-12-31¥9m
Drug Discovery Businessreportable segmentdepreciation2024-01-01 → 2024-12-31¥8m
Drug Discovery Businessreportable segmentsegment assetsat 2024-12-31¥291m
Drug Discovery Businessreportable segmentsegment profit2024-01-01 → 2024-12-31−¥2.0bn
Drug Discovery Support Businessreportable segmentcapex2024-01-01 → 2024-12-31¥9m
Drug Discovery Support Businessreportable segmentdepreciation2024-01-01 → 2024-12-31¥23m
Drug Discovery Support Businessreportable segmentrevenue2024-01-01 → 2024-12-31¥636m
Drug Discovery Support Businessreportable segmentrevenue external2024-01-01 → 2024-12-31¥636m
Drug Discovery Support Businessreportable segmentsegment assetsat 2024-12-31¥566m
Drug Discovery Support Businessreportable segmentsegment profit2024-01-01 → 2024-12-31−¥34m
—segment totalcapex2024-01-01 → 2024-12-31¥18m
—segment totaldepreciation2024-01-01 → 2024-12-31¥31m
—segment totalrevenue2024-01-01 → 2024-12-31¥636m
—segment totalrevenue external2024-01-01 → 2024-12-31¥636m
—segment totalsegment assetsat 2024-12-31¥857m
—segment totalsegment profit2024-01-01 → 2024-12-31−¥2.1bn
Drug Discovery Businessreportable segmentemployeesat 2025-12-3132 pure
Drug Discovery Support Businessreportable segmentemployeesat 2025-12-3117 pure

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,288
ItemContextValueUnit
Changes in number of issued shares stated capital etc (text)FilingDateInstantText · Plus
Shareholding by shareholder category (text)FilingDateInstantText · Plus
Major shareholders (text)FilingDateInstantText · Plus
Name major shareholdersCurrentYearInstant_No1MajorShareholdersMember
Original text (Japanese)MSIP CLIENT SECURITIES（常任代理人　モルガン・スタンレーMUFG証券株式会社）
Address major shareholdersCurrentYearInstant_No1MajorShareholdersMember25 CABOT SQUARE, CANARY WHARF, LONDON E14 4QA, U.K.
Name major shareholdersCurrentYearInstant_No2MajorShareholdersMember
Original text (Japanese)川村　剛
Address major shareholdersCurrentYearInstant_No2MajorShareholdersMember
Original text (Japanese)東京都町田市
Name major shareholdersCurrentYearInstant_No3MajorShareholdersMember
Original text (Japanese)小野薬品工業株式会社
Address major shareholdersCurrentYearInstant_No3MajorShareholdersMember
Original text (Japanese)大阪府大阪市中央区道修町2丁目1番5号
Name major shareholdersCurrentYearInstant_No4MajorShareholdersMember
Original text (Japanese)上原　俊彦
Address major shareholdersCurrentYearInstant_No4MajorShareholdersMember
Original text (Japanese)東京都港区
Name major shareholdersCurrentYearInstant_No5MajorShareholdersMember
Original text (Japanese)堀田　和男
Address major shareholdersCurrentYearInstant_No5MajorShareholdersMember
Original text (Japanese)愛知県岡崎市
Name major shareholdersCurrentYearInstant_No6MajorShareholdersMember
Original text (Japanese)吉野　公一郎
Address major shareholdersCurrentYearInstant_No6MajorShareholdersMember
Original text (Japanese)大阪府吹田市
Name major shareholdersCurrentYearInstant_No7MajorShareholdersMember
Original text (Japanese)小川　義水
Address major shareholdersCurrentYearInstant_No7MajorShareholdersMember
Original text (Japanese)東京都千代田区
Name major shareholdersCurrentYearInstant_No8MajorShareholdersMemberText · Plus
Address major shareholdersCurrentYearInstant_No8MajorShareholdersMemberText · Plus
Name major shareholdersCurrentYearInstant_No9MajorShareholdersMemberText · Plus
Address major shareholdersCurrentYearInstant_No9MajorShareholdersMember2 KING EDWARD STREET, LONDON EC1A 1HQ UNITED KINGDOM
Name major shareholdersCurrentYearInstant_No10MajorShareholdersMember
Original text (Japanese)鈴木　隆啓
Address major shareholdersCurrentYearInstant_No10MajorShareholdersMember
Original text (Japanese)愛知県名古屋市中区
Issued shares voting rights (text)FilingDateInstantText · Plus
Description issued shares voting rightsCurrentYearInstant_SharesWithNoVotingRightsMember－
Description issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember－
Description issued shares voting rightsCurrentYearInstant_SharesWithRestrictedVotingRightsOtherMember－
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember
Original text (Japanese)自己保有株式
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember
Original text (Japanese)権利内容に何ら限定のない当社における標準的となる株式
Description issued shares voting rightsCurrentYearInstant_OrdinarySharesSharesLessThanOneUnitMember－
Treasury shares etc (text)FilingDateInstantText · Plus
Name of shareholder treasury shares etcCurrentYearInstant_Row1Member
Original text (Japanese)カルナバイオサイエンス株式会社
Address of shareholder treasury shares etcCurrentYearInstant_Row1Member
Original text (Japanese)神戸市中央区港島南町一丁目5番5号
Classes of shares etc (text)FilingDateInstantText · Plus
Acquisitions by resolution of shareholders meeting (text)FilingDateInstantText · Plus
Acquisitions by resolution of board of directors meeting (text)FilingDateInstantText · Plus
Acquisitions not based on resolution of shareholders meeting or board of directors meeting (text)FilingDateInstantText · Plus
Disposals or holding of acquired treasury shares (text)FilingDateInstantText · Plus
Dividend policy (text)FilingDateInstantText · Plus
Overview of corporate governance (text)FilingDateInstantText · Plus
Corporate governance company with audit and supervisory committee (text)FilingDateInstantText · Plus
Information about officers (text)FilingDateInstantText · Plus
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000YoshinoKohichiroMember
Original text (Japanese)代表取締役社長
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000YoshinoKohichiroMember
Original text (Japanese)吉野　公一郎
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000YoshinoKohichiroMember1949-03-25
Career summary information about directors and corporate auditors (text)FilingDateInstant_jpcrp030000-asr_E00987-000YoshinoKohichiroMemberText · Plus
Term of office information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000YoshinoKohichiroMember
Original text (Japanese)(注)3
Official title or position information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000SawaMasaakiMember
Original text (Japanese)取締役チーフ サイエンティフィック オフィサー
Name information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000SawaMasaakiMember
Original text (Japanese)澤　匡明
Date of birth information about directors and corporate auditorsFilingDateInstant_jpcrp030000-asr_E00987-000SawaMasaakiMember1970-12-07

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2024-12-31pass rounding
balance sheet identityconsolidated 2025-12-31pass rounding
balance sheet identitynon_consolidated 2024-12-31pass rounding
balance sheet identitynon_consolidated 2025-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-12-31pass
statement vs summary · net assetsconsolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2023-12-31pass
statement vs summary · net assetsnon_consolidated 2024-12-31pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-12-31pass
statement vs summary · net income attributable to parentconsolidated 2025-01-01/2025-12-31pass
statement vs summary · operating cash flowconsolidated 2024-01-01/2024-12-31pass
statement vs summary · operating cash flowconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-12-31pass
statement vs summary · revenueconsolidated 2025-01-01/2025-12-31pass
statement vs summary · revenuenon_consolidated 2024-01-01/2024-12-31pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-12-31pass
statement vs summary · total assetsconsolidated 2024-12-31pass
statement vs summary · total assetsconsolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2024-12-31pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass